AGC Biologics
Buying intent
43 tracked signals | Top 15 topics are below | Sales and Marketing are carrying most of it.
Attention by team
LinkedIn activity, by teamWhere AGC Biologics's own people are actually spending their attention, by team, by topic. Bands run Low to High against the busiest pairing on this page, and each cell also shows how much of that team's own activity it represents.
Topics being researched
30-day windowEvery tracked topic, ranked by volume, not by our guess at what matters. Confidence is the classifier's own certainty that a signal belongs where we've filed it.
8d ago
8d ago
8d ago
28d ago
15d ago
14d ago
19d ago
11d ago
30d ago
18d ago
15d ago
30d ago
8d ago
19d ago
8d ago
Need intent for a specific topic or industry?
We track the full taxonomy across every account in the graph — including themes not shown on this page.
Who's active at AGC Biologics
verified title on fileTitles, seniority and topic straight from each person's own activity, with a LinkedIn link so you can check any of them yourself.
See everyone, not just the first 10
16 people across every department at AGC Biologics, plus a LinkedIn profile link for each.
Primary products / business lines
LinkedIn company profileAGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as we work side-by-side with our clients and partners to provide friendly and expert services. We provide world-class development and manufacturing of mammalian and microbial-based therapeutic proteins, plasmid DNA (pD
New capability sought
Employee posts (LinkedIn)Quality Management
Top accounts researching AGC Biologics
names withheld on the public pageThese are companies whose own people brought up AGC Biologics unprompted, not accounts we guessed might be interested. We can't yet tell an implementation partner from a genuine buyer here, names unlock along with the buyer profile below.
474 companies · 1,470 people are researching Cell Therapy
AGC Biologics's own team shows 3 signals on this topic. No one outside AGC Biologics has been seen researching the company by name yet — so this is the market it sits in, not a list of its buyers.
- Gene Therapy571 cos · 1,568 people
- Pharmaceutical5,568 cos · 20,395 people
Buyer profile
company size · seniorityCompany size and how senior the people involved are, the two things that decide whether this is a real deal. Competitor overlap isn't computed yet for this account.
Buying committee functions
Employee job titles (LinkedIn)Sales — 4 people; IT — 2 people; Operations — 1 person; Security — 1 person; Marketing — 1 person; Engineering — 1 person
What's been said
public posts mentioning AGC BiologicsUp to 9 public excerpts naming AGC Biologics from the past 365 days, across LinkedIn, Reddit, X, YouTube and other public sources.
I had the distinct pleasure of catching up with Elizabeth White and Jenna Dale, MBA from the Orphan Therapeutics Accelerator at #ASGCT2026 . The Orphan Therapeutics Accelerator (OTXL) utilizes their non-profit status and related incentives to obtain, fund and complete development of shelved therapies at low cost through a network of affiliated partners (Orphan ClinDevNet) to the benefit of patients fighting #ultrararediseases . AGC Biologics is proud to be a partner and engaged in the Orphan ClinDevNet. https://lnkd.in/gYfBHxxP
May 2026Meet with Dirk Hoegaerts PhD Olivier Dezutter Marijana Golubovic, PhD MBA from our European team at CDMO Live Europe in Rotterdam next week! AGC Biologics #FriendlyCDMO
May 2026Back in Basel!!! Excited to be attending the Swiss Biotech Day and representing AGC Biologics. It’s a great opportunity to connect with industry leaders, exchange ideas, and explore the latest trends and innovations in biotech and the CDMO world. Looking forward to inspiring conversations and building valuable new connections. If you’ll be there, feel free to reach out! #AGC #AGCBiologics #SBD #Basel #Biotech #CDMO #Networking
Apr 2026AGC Biologics continues to expand its global CDMO footprint with a new site in Yokohama, Japan. Scheduled to be GMP‑ready in 2027, the facility will significantly enhance mammalian, cell therapy, and mRNA capabilities, including one of Japan’s largest single‑use bioreactor installations. This investment strengthens AGC Biologics’ global network and supports growing demand for advanced biologics across the Asia‑Pacific region. An exciting step forward for patients, partners, and next‑generation therapies. #CDMO #BiologicsManufacturing #CellTherapy #mRNA #AGCBiologics
Apr 2026I’ll be making my way to AGC Biologics #Yokohama facility soon to see the progress and meet the teams turning promise into reality. #CGT #CellandGeneTherapy #CDMO #CellTherapy #Japan #Mammalian #GMP https://lnkd.in/ga4ZZbr5
Apr 2026